Tag Archives: chemotherapy
Phase II Trial of Phenoxodial Complete
INTRODUCTION: Chemoresistance is a major limitation in the treatment of ovarian cancer. Phenoxodiol is a novel biomodulator capable of reversing chemoresistance in vitro and in vivo. In this study, we … Continue reading
Results of a Third Phase III Trial of Avastin in Ovarian Cancer Released
Genentech, a member of the Roche group, announced that a third Phase III trial of Avastin in ovarian cancer met its endpoint of improvement in progression free survivial. See the … Continue reading
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
Background: A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian … Continue reading
Chemosensitivity Assays for Ovarian Cancer
Point: Chemosensitivity Assays Have a Role in the Management of Recurrent Ovarian Cancer In this era of personalized medicine, patients with recurrent ovarian cancer deserve better than the 25% response … Continue reading
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients
Background: Because it is insufficiently clear whether BRCA-associated epithelial ovarian cancer (EOC) is more chemosensitive than sporadic EOC, we examined response to chemotherapy, progression-free survival (PFS) and overall survival (OS) … Continue reading
Randomized Phase III Clinical Trial Evaluating Weekly Cisplatin for Advanced Epithelial Ovarian Cancer
This randomized, open label, phase III clinical trial (1988–1992) compared the efficacy and safety of a dose-dense regimen of single-agent cisplatin with a standard 3-weekly schedule in first-line chemotherapy for … Continue reading
Study examines end-of-life care for cancer patients
Many in their final days receive costly, aggressive treatments they may not want, according to researchers at the Dartmouth Atlas of Health Care. In California, Los Angeles County had the … Continue reading
Posted in News
Also tagged cost of care, outcomes, quality of life, support, treatment
Leave a comment
Use of Paclitaxel for Advanced Ovarian Cancer in Clinical Practice: Analysis of 541 Patients. Results from a German Multi-centre Observational Study
Paclitaxel is one of the most common antitumour agents paclitaxel for the treatment of primary and relapsed ovarian cancer. Based on a German multicentre observational study, this article reflects the … Continue reading
Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel
Background Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a novel combination compared with standard frontline therapy. Methods Women aged 75 years or younger with newly … Continue reading
Early versus delayed treatment of relapsed ovarian cancer
Background Serum CA125 concentration often rises several months before clinical or symptomatic relapse in women with ovarian cancer. In the MRC OV05/EORTC 55955 collaborative trial, we aimed to establish the … Continue reading
New White Paper Issued on Ovarian Cancer
The Society of Gynecologic Oncologists (SGO) has issued a comprehensive white paper — as part the organization’s professional Gynecologic Cancer Collaborative education program — that provides an overview of and … Continue reading
Posted in News
Also tagged biomarkers, clinical trials, early detection, Funding, Research, risk, science, symptoms, treatment
Leave a comment
Avastin helps in ovarian cancer but effects fade
Roche’s blockbuster drug Avastin helps women with ovarian cancer live longer without their disease getting worse, but its effect peaks at 12 months and then diminishes, researchers said on Monday. … Continue reading
